DATE: March 3, 2006

TO: Thomas Laughren, M.D., Director
Division of Psychiatry Products, HFD-130
Office of New Drugs (OND)
and
M. Dianne Murphy, M.D.
Director, Office of Pediatric Therapeutics (OPT), OIASI
Office of the Commissioner
and
Solomon Iyasu, M.D., M.P.H., Acting Deputy Director
Division of Pediatric Drug Development
Office of Counter-Terrorism and Pediatric Drug Development
(OCTAP)

THROUGH: Mark Avigan, M.D., C.M., Director
Division of Drug Risk Evaluation (DDRE)
Office of Drug Safety (ODS)

FROM: Andrew Mosholder, M.D., M.P.H., Epidemiologist

SUBJECT: Psychiatric Adverse Events in Clinical Trials of Drugs for
Attention Deficit Hyperactivity Disorder (ADHD)

PID: D060163
Table 1. Drugs indicated for ADHD included in this review

<table>
<thead>
<tr>
<th>Approved Products</th>
<th>Company</th>
<th>Date of Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA #</td>
<td>Name</td>
<td></td>
</tr>
<tr>
<td>21-303</td>
<td>Adderall XR (mixed salts of a single entity amphetamine product) Extended-Release Capsules</td>
<td>Shire Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>21-278</td>
<td>Focalin (dexamphetamine HCl) Tablets</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>21-802</td>
<td>Focalin XR (dexamphetamine HCl) Extended-Release Capsules</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>21-259</td>
<td>Metadate CD (methylphenidate HCl) Extended-Release Capsules</td>
<td>UCB Pharma, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pending NDAs/sNDAs</th>
<th>Company</th>
<th>Date of Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-717 S-019</td>
<td>Provigil (modafinil) Tablets</td>
<td>Cephalon, Inc.</td>
</tr>
<tr>
<td>21-514</td>
<td>Methylphenidate transdermal system (MTS)</td>
<td>Noven Pharmaceuticals, Inc (Shire is a co-development partner with Noven)</td>
</tr>
</tbody>
</table>
1 EXECUTIVE SUMMARY 4

2 BACKGROUND 5

2 BACKGROUND 5

3. METHODS 5

4. RESULTS 7

Summary results 7

A. Concerta 10

B. Metadate 11

C. Methylphenidate transdermal system (MTS) 12

D. Modafinil 13

E. Adderall XR 16

F. Atomoxetine 17

G. Ritalin LA 22

H. Focalin 22

5. CONCLUSIONS 24
1 EXECUTIVE SUMMARY

In follow-up to the June 2005 Pediatric Advisory Committee meeting discussion of adverse events with Concerta, it was decided to conduct a review of psychiatric adverse events with drugs for attention deficit hyperactivity disorder (ADHD). Results of the analysis of postmarketing reports will be presented separately. This consult summarizes the data from approximately 90 clinical trials that was submitted in response to the agency’s request. Sponsors of marketed products for ADHD and drugs under review for that indication were asked to search their clinical trial databases for adverse psychiatric events in three primary categories: psychosis and mania, suicidal events, and aggression. This search was conducted electronically using selected, prespecified adverse event terms. They were also asked to search their databases for additional miscellaneous psychiatric events if the outcome was serious. Data on the duration of exposure to treatment in the trials and subject characteristics were also requested, as were clinical descriptions of the events and descriptions of the clinical trials in the ADHD development programs. Data were pooled within development programs to estimate the rates of the events of interest. The findings are subject to the usual limitations of such safety analyses, which include potential lack of consistency of ascertainment of adverse events across the various trials, the possibility of misclassification of cases, and statistical power limitations imposed by the sample sizes.

With these limitations in mind, specific observations about these clinical trial data are as follows. With respect to the clinical trial design, a large number of the controlled trials required subjects who were known to respond to stimulants, or who had no history of intolerance to stimulants. Also, many of the controlled trials were of very short duration. These factors limit the utility and external generalizability of the safety datasets obtained from the trials. With respect to specific findings, suicidal events were more frequent with atomoxetine and modafinil treatment than with placebo. It should be noted that there were no completed suicides in ADHD trials with these drugs (one completed suicide was reported in a placebo patient in an atomoxetine trial for another indication). Aggressive events were more frequent with the methylphenidate transdermal patch, and to a lesser degree with atomoxetine, than with placebo. None of these imbalances in rates reached customary levels of statistical significance in this analysis, although Lilly’s previous analysis of suicidal events with atomoxetine did show a statistically significant association. For aggression events, there was little evidence in these trials that drug treatment reduced their frequency relative to placebo; only for modafinil was the event rate numerically lower than for placebo and this was not statistically significant. With respect to psychosis and mania events, although the numbers of such events with drug treatment were small, the complete absence of such events with placebo treatment was notable. For 4028 pediatric ADHD patients in these trials, there were no such events in 425 person-years of aggregated placebo treatment. Similarly, there were no psychosis or mania events in these trials among adult ADHD patients receiving placebo. Psychosis/mania events occurred during double-blind treatment with every compound except Adderall XR (although there were psychosis/mania events with open label
Adderall XR treatment). Furthermore, as noted above, some subjects in Phase I studies of these drugs experienced this type of event.

Patients and physicians should be aware of the possibility that these events, when they arise in the course of drug treatment of ADHD, may represent adverse reactions to drugs. In terms of future clinical trial designs, it should be borne in mind that short-duration trials and trials which exclude subjects who are naïve to this class of drug, while they may be efficient for determining efficacy, have limitations for defining the safety profile of the drug.

2 BACKGROUND

The present effort to characterize psychiatric adverse events among patients treated with drugs for attention deficit hyperactivity disorder (ADHD) arose from a discussion at the June 30, 2005 meeting of FDA’s Pediatric Advisory Committee. The rationale for this project was summarized in the letter FDA’s Division of Psychiatry Products sent to the sponsors of products for ADHD, in September 2005:

At a June 30, 2005 meeting of the Pediatric Advisory Committee, a concern was raised about reports of psychiatric adverse events occurring in patients being treated with various drug products for ADHD. The reports considered at that meeting were for the drug Concerta, but it was acknowledged that similar reports have been made for other ADHD products. Although some psychiatric adverse events are already mentioned in the labeling for various ADHD products, there was general support for the view that labeling may need to be enhanced to better characterize these events. However, there was also agreement that such labeling changes should await a more comprehensive review of psychiatric events for ADHD products. In order to facilitate this more comprehensive review, we are requesting psychiatric adverse event data for various products approved for the treatment of ADHD.¹

An analysis of postmarketing reports of adverse psychiatric events will be presented in a separate document. This document will present data on the psychiatric adverse events of interest from the clinical trial programs for the various ADHD products.

3. METHODS

In the Information Request letters sent to the sponsors of ADHD drugs, the Division of Psychiatry Products asked the sponsors to conduct a search of their clinical trial databases for the adverse events of interest. The primary categories of adverse events to be analyzed were (1) psychosis and mania; (2) suicidal events; and (3) aggression. In addition, sponsors were asked to provide data on serious adverse events (i.e., those meeting the regulatory criteria for “serious”) for a variety of miscellaneous psychiatric outcomes. Sponsors were to perform a string search of their electronic clinical trial databases for both preferred adverse event terms (e.g., MedDRA, COSTART) and investigator verbatim terms that might reflect one of the categories of interest. The

¹ Dr. Thomas Laughren, FDA Division of Psychiatry Products, September 14, 2005.
The sponsors were instructed to enumerate events in these categories for both open label and double blind clinical trials. Events occurring either within 48 hours of the end of study treatment or within 30 days of the end of study treatment were to be enumerated separately. The sponsors were asked to provide synopses of the clinical trials, to assist in classifying the type of study for the purpose of aggregating data across trials. Sponsors were also asked to stratify data from their trials by age and gender subgroups, and to provide the duration of treatment (person-days) for each age and gender strata by trial, along with a count of patients who had events meeting the criteria for one of the categories of interest. However, we found that in some cases sponsors provided exposure time in person-days for each dose administered during the trial, resulting in the counting of some patients more than once according to how many doses they had received in that trial. In such instances the number of patients treated in the trial was determined from the clinical trial synopsis. Clinical trial exposure was to be classified as open label extension, open label run-in, or double blind. Patients with more than one event were to be counted only once per trial per category. In addition, the sponsor was asked to provide an

---

2 PID D050243
accompanying listing of patients who had such events, with clinical information including patient characteristics, dose, concomitant medications, whether the event required discontinuation of treatment, and whether the event met criteria for “serious.” (However, some sponsors provided this listing without specifying the category in which the event had been counted, making it difficult to reconcile the summary data with the listing of individual events.) Sponsors were also requested to provide clinical summaries of cases involving a serious outcome or premature discontinuation of treatment.

The drug products included in this analysis are those listed at the beginning of this document. All sponsors provided the requested data.

The submitted data were reviewed and data on the frequency of events were aggregated across trials within each product’s clinical development program. Pooling across development programs was avoided because of apparent differences between the several development programs in patient populations and ascertainment of the selected adverse events. The event data were too sparse to permit a meaningful meta-analysis stratified by trial, as there were many trials with no events. However, the pediatric placebo exposure was aggregated to provide an estimate of the rates of events in a cohort of unmedicated pediatric ADHD patients. Statistical computing was accomplished with Microsoft Excel, JMP 5.1, and Stata 7.0.

4. RESULTS

Summary results

The data requests yielded data on 100 separate clinical trials in the development programs for these products. The table on the following page presents an overview of the clinical trials and the events. Note that this table includes all age groups and omits active control treatments for simplicity.
Table 3. Summary of ADHD clinical trials and psychiatric adverse events (all age groups)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type of trial</th>
<th>No. of Trials</th>
<th>Duration of trials (range)</th>
<th>Category of exposure</th>
<th>N Patient-years</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concerta DB</td>
<td>4</td>
<td>6-28 dys</td>
<td>Placebo</td>
<td>Drug DB</td>
<td>317</td>
<td>10.20</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>≤ 12 mos.</td>
<td>Drug DB</td>
<td>Drug OL</td>
<td>321</td>
<td>12.68</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2824</td>
<td></td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Metadate CD</td>
<td>DB</td>
<td>4</td>
<td>7-21 dys</td>
<td>Placebo</td>
<td>572</td>
<td>19.44</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>2</td>
<td>NS</td>
<td>Drug DB</td>
<td>493</td>
<td>19.13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>322</td>
<td>19.55</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>464</td>
<td>23.84</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MTS</td>
<td>DB</td>
<td>8</td>
<td>1-49 dys</td>
<td>Placebo</td>
<td>471</td>
<td>30.26</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>4</td>
<td>NS</td>
<td>Drug DB</td>
<td>617</td>
<td>341.97</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Modafinil</td>
<td>DB</td>
<td>6</td>
<td>1-9 wks</td>
<td>Placebo</td>
<td>366</td>
<td>39.87</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>3</td>
<td>&lt;1 yr</td>
<td>Drug DB</td>
<td>772</td>
<td>85.50</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>924</td>
<td>383.53</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Adderall XR</td>
<td>DB</td>
<td>7</td>
<td>1-4 wks</td>
<td>Placebo</td>
<td>678</td>
<td>28.00</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>6</td>
<td>&lt;2 yrs</td>
<td>Drug DB</td>
<td>1236</td>
<td>77.18</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>5177</td>
<td>1767.47</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>DB</td>
<td>20</td>
<td>≤ 78 wks</td>
<td>Placebo</td>
<td>1443</td>
<td>350.73</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>10</td>
<td>&lt; 96 wks</td>
<td>Drug DB</td>
<td>2459</td>
<td>654.87</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>5270</td>
<td>5095.27</td>
<td>12</td>
<td>44</td>
</tr>
<tr>
<td>Ritalin LA</td>
<td>DB</td>
<td>5</td>
<td>1-14 dys</td>
<td>Placebo</td>
<td>259</td>
<td>11.31</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>1</td>
<td>NS</td>
<td>Drug DB</td>
<td>383</td>
<td>25.66</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>125</td>
<td>25.95</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>d-MPH</td>
<td>DB</td>
<td>8</td>
<td>≤ 49 dys</td>
<td>Placebo</td>
<td>468</td>
<td>53.24</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>OL</td>
<td>5</td>
<td>&lt; 1 yr</td>
<td>Drug DB</td>
<td>588</td>
<td>64.75</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drug OL</td>
<td></td>
<td>740</td>
<td>362.09</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviations: DB double blind, OL open label, NS not specified, MTS methylphenidate transdermal system, d-MPH dextromethylphenidate
Summary of comparison of rates in double blind, pediatric trials

The following summary table displays the comparisons between the drug products and placebo for the three categories of events, within each development program, for pediatric subjects. Active controls were omitted from this summary. At the bottom of the table the pooled results for placebo are shown.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
<th>Psychosis/mania events/100 pt-yrs</th>
<th>Suicidal events/100 pt-yrs</th>
<th>Aggression events/100 pt-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>317</td>
<td>10.2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Concerta</td>
<td>321</td>
<td>12.68</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Placebo</td>
<td>572</td>
<td>19.44</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0.00</td>
<td>0.00</td>
<td>15.43</td>
</tr>
<tr>
<td>Metadate CD</td>
<td>493</td>
<td>19.13</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>0.00</td>
<td>0.00</td>
<td>15.68</td>
</tr>
<tr>
<td>Placebo</td>
<td>464</td>
<td>23.84</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0.00</td>
<td>0.00</td>
<td>4.19</td>
</tr>
<tr>
<td>MTS</td>
<td>471</td>
<td>30.26</td>
<td>4</td>
<td>0</td>
<td>6</td>
<td>13.22</td>
<td>0.00</td>
<td>19.83</td>
</tr>
<tr>
<td>Placebo</td>
<td>308</td>
<td>32.55</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>0.00</td>
<td>0.00</td>
<td>15.36</td>
</tr>
<tr>
<td>Modafinil</td>
<td>664</td>
<td>75.11</td>
<td>2</td>
<td>4</td>
<td>9</td>
<td>2.66</td>
<td>5.33</td>
<td>11.98</td>
</tr>
<tr>
<td>Placebo</td>
<td>599</td>
<td>23.34</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>0.00</td>
<td>0.00</td>
<td>25.71</td>
</tr>
<tr>
<td>Adderall XR</td>
<td>1026</td>
<td>63.78</td>
<td>0</td>
<td>1</td>
<td>18</td>
<td>0.00</td>
<td>1.57</td>
<td>28.22</td>
</tr>
<tr>
<td>Placebo</td>
<td>1056</td>
<td>256.02</td>
<td>0</td>
<td>3</td>
<td>15</td>
<td>0.00</td>
<td>1.17</td>
<td>5.86</td>
</tr>
<tr>
<td>Atomoxetine</td>
<td>1939</td>
<td>524.64</td>
<td>4</td>
<td>8</td>
<td>45</td>
<td>0.76</td>
<td>1.52</td>
<td>8.58</td>
</tr>
<tr>
<td>Placebo</td>
<td>259</td>
<td>11.31</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0.00</td>
<td>8.84</td>
<td>0.00</td>
</tr>
<tr>
<td>Ritalin LA</td>
<td>383</td>
<td>25.66</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>7.79</td>
<td>0.00</td>
<td>7.79</td>
</tr>
<tr>
<td>Placebo</td>
<td>415</td>
<td>48.47</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>d-MPH</td>
<td>420</td>
<td>49.73</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2.01</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Placebo (Pooled across drugs)</td>
<td>3990</td>
<td>425.11*</td>
<td>0</td>
<td>4</td>
<td>30</td>
<td>0</td>
<td>0.94</td>
<td>7.06</td>
</tr>
</tbody>
</table>

*Age categories varied slightly by sponsor, but subgroup exposures may be summarized as follows: adolescent males 58 pyrs. adolescent females 18 pyrs, male children 274 pyrs, female children 75 pyrs.
Summaries of psychiatric adverse events by clinical development program

In the following pages, the findings with respect to the psychiatric adverse events of interest are presented for each drug product.

A. Concerta (NDA 21-121, McNeil)

Concerta is an extended release formulation of methylphenidate marketed by McNeil. Safety and efficacy studies contributing data to this analysis are summarized in Appendix Table A. Omitted from the analysis were studies in which the primary focus was on clinical pharmacology or bioavailability. Also, McNeil omitted from their response data from studies in which no Concerta was administered; i.e., involving non-Concerta formulations of methylphenidate only. In addition, there were a total of 17 non-U.S. studies of Concerta for which only limited data were available, and these have been omitted from the analysis. (The information currently available to the sponsor indicates no adverse events of interest occurred among subjects in these trials, but data are incomplete.)

It will be noted from the appendix table that all of the double blind exposure to Concerta in these trials occurred among patients who were already methylphenidate users, or had undergone open label treatment with methylphenidate prior to randomization (i.e., in study 011146).

The table below provides a summary of the adverse events of interest in the safety and efficacy trials with Concerta. There was only one relevant event during double blind treatment, an aggression event associated with use of Ritalin as an active control.

Table A. Frequency of patients experiencing selected psychiatric events in Concerta clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>317</td>
<td>10.20</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>321</td>
<td>12.68</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Ritalin</td>
<td>236</td>
<td>9.69</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>OL</td>
<td>Concerta</td>
<td>2824</td>
<td>1397.40</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>OL</td>
<td>Ritalin</td>
<td>76</td>
<td>11.81</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>OL</td>
<td>Atomoxetine</td>
<td>472</td>
<td>27.94</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>OL run in</td>
<td>Concerta</td>
<td>330</td>
<td>16.96</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Five of the 52 aggressive events occurring during open label Concerta treatment were deemed serious.
The only study to enroll adult (>18 years old) ADHD subjects was open label study C99018, and in that study there were no events from these three categories among the adult subjects.

There were no miscellaneous adverse events deemed “serious” during double blind treatment. During open label treatment, one atomoxetine treated subject (172101 in study 12101) developed severe fearfulness that was considered serious, and Concerta-treated patient 19603 in the same study developed emotional distress that was considered serious and persisted post-treatment (see below). This patient, an 11-year old boy, was psychiatrically hospitalized and was eventually diagnosed with bipolar disorder, mixed with psychotic features.

There were a few relevant adverse events observed post-treatment (these are not shown in the table above). No events meeting the search criteria occurred within 48 hours of treatment discontinuation in these trials. With respect to events occurring between 48 hours and 30 days after treatment discontinuation, one subject became delusional five days after discontinuing Concerta, one subject was hospitalized for depression with a suicidal attempt 25 days after discontinuing Concerta, and in the “Miscellaneous” category, subjects 19603 (see above) and 19604 in open label study 12101 experienced “emotional distress” that was considered a serious adverse event 23 and 20 days, respectively, after study treatment ended. The narrative for patient 19604 also noted violent behaviors requiring psychiatric hospitalization, although the event was not categorized under aggression; the patient’s diagnoses included bipolar disorder and intermittent explosive disorder.

**B. Metadate CD (NDA 21-259, UCB Pharma, Inc.)**

Metadate CD is an extended release preparation of methylphenidate. The sponsor’s development program included 4 randomized, double blind efficacy trials and 2 open label safety trials; only pediatric subjects were enrolled in Metadate CD safety and efficacy trials. Appendix table B provides an overview of the clinical trials for studies in ADHD patients. All double-blind trials enrolled subjects who had been treated previously with methylphenidate. The sponsor’s search for the adverse psychiatric events of interest yielded no psychosis or mania events, no suicidal events, and 6 aggression events in double blind trials (3 each with Metadate and placebo). There were an additional 6 aggression events with open label treatment. All of the aggression events in both double blind and open label studies occurred in boys. There was only one serious psychiatric adverse event in these studies, in a Metadate-treated patient (termed “abnormal behavior”) which resulted in hospitalization (Study CD00500 / Patient #2003). This event was counted as aggression, in the open-label trial category.

There were no relevant psychiatric events in the sponsor’s bioavailability/pharmacokinetic trials, and no relevant events were reported up to 30 days post-treatment.

The following is a summary of the exposures and events in the Metadate CD safety and efficacy clinical trial program.
Table B. Frequency of patients experiencing selected psychiatric events in Metadate CD clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo*</td>
<td>572</td>
<td>19.44</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Metadate CD</td>
<td>493</td>
<td>19.13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Ritalin</td>
<td>158</td>
<td>7.61</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>180</td>
<td>3.29</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>OL</td>
<td>Metadate CD</td>
<td>322</td>
<td>19.55</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*includes single-blind placebo treatment in study MAI00104

In addition to the events enumerated above, patient 11-218 in study CD00600 experienced euphoria on the first day of treatment with placebo, and patient 1-10 in study CD00700 experienced euphoria on day 1 of Metadate CD, but these events were not included in the category of psychosis/mania as enumerated above.

C. Methylphenidate transdermal system (MTS) (Noven, NDA 21-514)

The methylphenidate transdermal system (MTS) is a patch that delivers methylphenidate through the skin and is worn throughout the day and removed in the evening. This product is not yet approved. The development program included 8 randomized efficacy trials and 3 completed open label safety trials. All ADHD safety and efficacy trials involved only pediatric subjects. The characteristics of these trials are summarized in Appendix table C, and the summary data on psychiatric adverse events of interest are summarized in the table below.

Table C. Frequency of patients experiencing selected psychiatric events in MTS clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>464</td>
<td>23.84</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>DB</td>
<td>MTS</td>
<td>471</td>
<td>30.26</td>
<td>4*</td>
<td>0</td>
<td>6**</td>
</tr>
<tr>
<td>DB</td>
<td>Ritalin</td>
<td>10</td>
<td>0.19</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>91</td>
<td>11.10</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Open</td>
<td>MTS</td>
<td>617</td>
<td>341.97</td>
<td>6</td>
<td>1</td>
<td>7</td>
</tr>
</tbody>
</table>

*Rate ratio undefined, rate difference 0.13/person year, p-value versus placebo 0.10 (Stata version 7.0)

**Rate ratio versus placebo 4.7, p-value 0.13 (Stata version 7.0).

Of the four psychosis/mania events during double blind treatment, two involved hallucinations, one a manic episode with hallucinations, and one paranoia. Two of the 7 aggression events occurring during open label treatment met criteria for “serious.” Although none of the 6 aggression events during double blind treatment met criteria for serious, one did result in a suspension from school.
Additionally, in study SPD485201 there was an open-label run-in period prior to randomization that enrolled 93 patients (80 eventually were randomized), and during this run-in period there were 2 aggression events.

There were also clinical data from 9 bioavailability studies (4 involving pediatric ADHD patients), and 2 special skin sensitization studies in healthy adults. Review of the sponsor’s listing of adverse events showed that in the biopharmaceutics trials, one child receiving Concerta, and 1 adult administered MTS buccaly experienced psychosis/mania events. In the two open-label special skin sensitization protocols, which together exposed 315 healthy adult volunteers, there were 6 psychosis/mania events and one aggression event. Data from a special study of abuse potential in adults (N17-007) showed 2 psychosis/mania events with MTS, and four such events with the active controls.

The sponsor identified no relevant adverse events occurring after treatment discontinuation. Also, there were no serious psychiatric adverse events in the miscellaneous category.

**D. Modafinil (NDA 20-717 S-019, Cephalon, Inc.)**

Modafinil (Provigil, marketed by Cephalon, Inc.) is a non-sympathomimetic stimulant marketed for the treatment of excessive daytime sleepiness associated with sleep disorders. An indication for ADHD is under review, and will be the topic at the March 23 Psychopharmacologic Drugs Advisory Committee meeting.

With respect to psychotic adverse reactions, the current modafinil labeling notes (in the Precautions section) one such episode in a normal volunteer:

> One healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of PROVIGIL and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation.3

Analysis of Psychiatric Adverse Events in Response to Approvable Letter

The sponsor provided the following analysis in reply to our September 14, 2005 request as part of their response to the approvable letter for the indication of ADHD.

---
3 Provigil prescribing information available at www.provigil.com
Table D1. Frequency of patients with psychiatric adverse events in ADHD trials  
(response to approvable letter)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>308</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>DB</td>
<td>Modafinil</td>
<td>664</td>
<td>2</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Open</td>
<td>Modafinil</td>
<td>799</td>
<td>2</td>
<td>0</td>
<td>14</td>
</tr>
</tbody>
</table>

Analysis in response to FDA request 9-14-05

The sponsor also provided data on the adverse events of interest in a separate submission 1-6-06, responding specifically to the agency’s request letter of 9-14-05. It appeared that this later submission included additional clinical trial data, although a list of the specific studies included was provided only for the 1-6-06 submission, so this could not be verified.

Table D2. Frequency of patients with psychiatric adverse events in ADHD trials  
(sponsor’s 1-6-06 submission)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>366</td>
<td>39.87</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>DB</td>
<td>Modafinil</td>
<td>772</td>
<td>85.50</td>
<td>2</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Open</td>
<td>Modafinil</td>
<td>924</td>
<td>383.53</td>
<td>2</td>
<td>0</td>
<td>14</td>
</tr>
</tbody>
</table>

There were no serious adverse events in the miscellaneous category.

There were more events in all categories among modafinil treated patients compared to placebo, but the exposure to modafinil was greater. It will be noted, however, that the frequency of these events during double blind treatment was higher than during open label treatment.

The table below displays the data for the subgroup of pediatric patients only (i.e., eliminating study 205 in adults, in which there were no events of interest).

Table D3. Frequency of pediatric patients with psychiatric adverse events in ADHD trials (from 1-6-06 submission)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>308</td>
<td>32.55</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>DB</td>
<td>Modafinil</td>
<td>664</td>
<td>75.11</td>
<td>2</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Open</td>
<td>Modafinil</td>
<td>799</td>
<td>369.35</td>
<td>2</td>
<td>0</td>
<td>14</td>
</tr>
</tbody>
</table>

It should be noted that the NDA review by the Division of Psychiatry Products identified two additional probable cases of aggression during double blind treatment, in study 207 (patients 410 and 411).4

4 Drs. June Cai and Glenn Mannheim, Division of Psychiatry Products
In addition, the sponsor noted that there were no events in the miscellaneous category that met criteria for “serious.”

With respect to events occurring after study treatment, one modafinil-treated subject (#410 in study 207) experienced formication (coded as psychosis) within 48 hours of treatment discontinuation, and one 6-year old female (subject 312-014016) was hospitalized for self-harmful behavior (putting a rope around her neck) two days after discontinuing open label treatment with modafinil. There were no psychiatric adverse events during the period from 48 hours to 30 days after treatment discontinuation.

One of the two psychosis/mania events during open label treatment required psychiatric hospitalization for a psychotic episode with suicidal ideation (patient 213-11002, an 8-year old boy who had a history of such symptoms, although this was apparently not known at study entry). This case was counted by the sponsor only in the psychosis/mania category, although it perhaps could have been counted as a suicidal event as well. The only two patients with serious psychiatric adverse events in these clinical trials were 312-014016 and 213-11002. (An additional case of suicidal ideation in a modafinil treated patient, requiring hospitalization, was included in the sponsor’s safety update for the ADHD supplement (patient 016001 from ongoing Study 312), but this apparently occurred after the cutoff date for the present data set.5)

Appendix table D displays the characteristics of the ADHD clinical trials. In addition, the sponsor provided data on the psychiatric events of interest from other indications. These data are summarized below.

**Table D4. Frequency of patients with selected psychiatric adverse events in studies of other indications**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Indication</th>
<th>Treatment</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
<th>Miscellaneous serious events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Excessive sleepiness</td>
<td>Placebo</td>
<td>96.65</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>DB</td>
<td>Excessive sleepiness</td>
<td>Modafinil</td>
<td>168.44</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Open</td>
<td>Excessive sleepiness</td>
<td>Modafinil</td>
<td>1988.31</td>
<td>4</td>
<td>6</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>DB</td>
<td>Other*</td>
<td>Placebo</td>
<td>26.56</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Other*</td>
<td>Modafinil</td>
<td>98.37</td>
<td>8</td>
<td>2</td>
<td>13</td>
<td>6</td>
</tr>
<tr>
<td>Open</td>
<td>Other*</td>
<td>Modafinil</td>
<td>89.98</td>
<td>10</td>
<td>3</td>
<td>12</td>
<td>3</td>
</tr>
</tbody>
</table>

*Clinical pharmacology, depression, dementia, head trauma, and other disorders

---

5 Dr. June Cai, FDA Division of Psychiatric Products, personal communication
E. Adderall XR (NDA 21-303, Shire)

Adderall and Adderall XR are formulations of mixed amphetamine salts. The active ingredient is a mixture of 25% l-amphetamine and 75% d-amphetamine. Adderall XR is an extended release, once-a-day formulation. There were no clinical safety and efficacy trial data available for Adderall, so the results below are for Adderall XR exclusively.

The Adderall XR development program included 3 randomized, double blind, placebo controlled trials in pediatric patients and one in adult ADHD patients. The Adderall XR safety and efficacy trials are summarized in Appendix table E.

The table below displays the summary data for the psychiatric events of interest.

Table E1. Frequency of patients experiencing selected psychiatric events in Adderall XR clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB Placebo</td>
<td>678</td>
<td>28.00</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>DB Adderall XR**</td>
<td>1236</td>
<td>77.18</td>
<td>0</td>
<td>1</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Open Adderall XR</td>
<td>5177</td>
<td>1767.47</td>
<td>14</td>
<td>8</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>DB Atomoxetine</td>
<td>108</td>
<td>4.83</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

*N not available  **includes 48 subjects in study 201 who received both Adderall and Adderall XR

The table below shows the data for the subgroup of trials involving only subjects of pediatric age.

Table E2. Frequency of patients experiencing events in pediatric trials

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB Placebo</td>
<td>599</td>
<td>23.34</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>DB Adderall XR*</td>
<td>1026</td>
<td>63.78</td>
<td>0</td>
<td>1</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Open Adderall XR</td>
<td>4233</td>
<td>1280.80</td>
<td>9</td>
<td>8</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>DB Atomoxetine</td>
<td>108</td>
<td>4.83</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

*includes 48 subjects in study 201 who received both Adderall and Adderall XR

There were relatively few events in the categories of psychosis/mania and suicidal events in the double blind trials. There were somewhat more aggression events, but the distribution of events between drug and placebo was roughly proportional to the exposures. Of the 26 aggression events during double blind treatment, 11 occurred in study 201, a laboratory school study. Conceivably, closer observation of the subjects in that setting might have led to more reports of aggressive behaviors.

One trial included in the data above involved pediatric patients with Oppositional Defiant Disorder. Although the data were included in the totals above, they will be noted here
separately since this is a different albeit related indication. Study 311 was a 4 week randomized, double blind, placebo controlled, parallel group study involving five treatment arms (four fixed doses of Adderall XR and placebo). There was one aggression category event among the 60 patients who received placebo, and one suicidal event and seven aggression events among the 237 patients treated with Adderall XR. The pattern of events did not appear dose-related.

The sponsor reported no adverse events of interest in any Phase 1 trials.

With respect to events occurring after the end of treatment, there were a total of 4 subjects with such events. Patient 027-002 in study 311, a 17 year old girl, made a suicide attempt (overdose) 4 days after discontinuing Adderall XR 30 mg. Patient 041-010 in study 302, an 8 year old girl, was hospitalized for suicidal threats and explosive temper one day after discontinuing Adderall XR 30 mg and beginning diazepam. Patient 102-021 in study 304, an adult who had discontinued Adderall XR for a hypomanic episode, developed suicidal ideation subsequently. Lastly, patient 455-001 in study 305, a 9 year old female, developed defiant behaviors after discontinuing Adderall XR.

There were 4 serious events in the “miscellaneous” category, all with open-label treatment (one “personality disorder” and 3 “depression” events). The three events coded as depression (in subject 007-026/study 302, a 9-year old female, and subject 320-009, study 305, 10 year old girl, and subject 027-002, study 315, 14 year old female) involved hospitalization for suicidal ideation, and perhaps could have been classified in the suicidal event category. Other serious adverse events, all with open label treatment, included 2 aggression events in boys, two suicidal events in adolescent females, and one event designated amphetamine psychosis in an adult male. One of the serious events in the aggression category (subject 010-006, study 302, 10 year old boy) involved not only aggression and threats to others but also threats of self harm.

Also with respect to classification, one event in study 305 described in the clinical narrative as leading to discontinuation was “aggression towards himself” (subject 276-003), but this was categorized as an aggression event.

F. Atomoxetine (Strattera, NDA 21-411, Lilly)

Atomoxetine is a specific norepinephrine reuptake inhibitor marketed for the indication of ADHD in both children and adults. A previous development program for the indication of depression in adults was not successful.

The current labeling for atomoxetine includes the following Warning regarding suicidal events in atomoxetine clinical trials:

Suicidal Ideation
STRATTERA increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of
STRATTERA in children and adolescents have revealed a greater risk of suicidal ideation early during treatment in those receiving STRATTERA. There were a total of 12 trials (11 in ADHD and 1 in enuresis) involving over 2200 patients (including 1357 patients receiving STRATTERA and 851 receiving placebo). The average risk of suicidal ideation in patients receiving STRATTERA was 0.4% (5/1357 patients), compared to none in placebo-treated patients. There was 1 suicide attempt among these approximately 2200 patients, occurring in a patient treated with STRATTERA. No suicides occurred in these trials. All events occurred in children 12 years of age or younger. All events occurred during the first month of treatment. It is unknown whether the risk of suicidal ideation in pediatric patients extends to longer-term use. A similar analysis in adult patients treated with STRATTERA for either ADHD or major depressive disorder (MDD) did not reveal an increased risk of suicidal ideation or behavior in association with the use of STRATTERA…

With respect to aggressive behaviors, the current labeling includes the following statement (under the Precautions section):

Aggressive Behavior or Hostility — Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no conclusive evidence that STRATTERA causes aggressive behavior or hostility, aggressive behavior or hostility was more frequently observed in clinical trials among children and adolescents treated with STRATTERA compared to placebo (overall risk ratio of 1.33 – not statistically significant). Patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

Lilly suicidal event analysis

The labeling cited above for suicidal ideation was based on an analysis by Lilly of suicidal events in atomoxetine randomized, double-blind trials, requested by FDA in December 2004, and completed and submitted by Lilly in September 2005. Briefly, their methods and findings were as follows. Adverse event preferred terms, verbatim terms and comment fields were searched for text strings that might represent suicidal behaviors or ideation. Two different sets of text string terms were used for these searches, one requested by FDA and one devised by Lilly. False positives returned by these searches were excluded by review, and the events were classified into one of several categories of self injury or suicidal ideation. Statistical testing was performed using the Mantel-Haenzel incidence difference test. The results for the pediatric and adult atomoxetine trials are shown in the table below. By the FDA criteria, there were a total of 6 events classified as suicidal behavior or ideation among atomoxetine treated pediatric patients (6/1357, 0.4%) versus no such events among 851 placebo-treated patients (p-value = 0.01). Of the six pediatric events, one involved suicidal behavior and 5 involved suicidal ideation.
Overall, there was not the same imbalance between drug and placebo in the adult trials that was observed in the pediatric trials. The events in adult trials included one adult completed suicide on placebo. By indication, only one event occurred in an adult ADHD trial (on placebo).

**Table F1. Lilly analysis of suicidal events in atomoxetine clinical trials**

<table>
<thead>
<tr>
<th>Category of events</th>
<th>Pediatric studies</th>
<th>Adult studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atomoxetine (n = 1357)</td>
<td>Placebo (n = 851)</td>
</tr>
<tr>
<td>Suicidal events, FDA definition</td>
<td>6 (0.4%)*</td>
<td>0</td>
</tr>
<tr>
<td>Suicidal events, Lilly definition</td>
<td>7 (0.5%)**</td>
<td>1 (0.1%)</td>
</tr>
</tbody>
</table>

*p-value versus placebo = 0.01          **p-value versus placebo = 0.07

Lilly analysis of hostility and aggression

In April 2005, Lilly submitted an analysis of hostility and aggression in their pediatric atomoxetine double blind clinical trials. As with the analysis described above, they searched their clinical trial preferred terms, verbatim terms and comments fields for a variety of text strings that possibly represented hostility or aggression. Events returned by the search were reviewed by two health care professionals blind to treatment, and were classified into one of 6 possible categories of hostility or aggression, or were excluded. This yielded the results displayed in the following table. The combined risk ratio for aggressive events (atomoxetine:placebo) was 1.33 (0.67-2.64).

**Table F2. Lilly analysis of aggression in atomoxetine pediatric clinical trials**

<table>
<thead>
<tr>
<th>Category of events</th>
<th>Frequency in pediatric double blind trials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atomoxetine (n = 1308)</td>
</tr>
<tr>
<td>Aggression and hostility, Lilly definition</td>
<td>21 (1.6%)</td>
</tr>
</tbody>
</table>

Response to September 2005 Data Request

The following tables display the results of the requested search. There were a total of 18 randomized, double blind trials of atomoxetine in pediatric patients with ADHD, and 3 such trials in adults. The ADHD safety and efficacy trials contributing data are summarized in Appendix table F.

The next table shows the summary results for all ages combined.
Table F3. Frequency of patients with psychiatric adverse events in adult and pediatric ADHD safety and efficacy trials (Lilly response to September 14, 2005 letter)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>1443</td>
<td>350.73</td>
<td>0</td>
<td>4</td>
<td>18</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine</td>
<td>2459</td>
<td>654.87</td>
<td>4</td>
<td>9</td>
<td>49</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine+Concerta</td>
<td>9</td>
<td>0.87</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine+Fluoxetine</td>
<td>114</td>
<td>11.92</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Fluoxetine</td>
<td>120</td>
<td>7.54</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>DB</td>
<td>Methylphenidate</td>
<td>515</td>
<td>69.21</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Open</td>
<td>Atomoxetine*</td>
<td>5270</td>
<td>5095.27</td>
<td>12</td>
<td>44</td>
<td>198</td>
</tr>
<tr>
<td>Run-in</td>
<td>Atomoxetine</td>
<td>812</td>
<td>177.80</td>
<td>2</td>
<td>3</td>
<td>47</td>
</tr>
</tbody>
</table>

*This total is for atomoxetine without other drugs; there were no events among the small numbers of patients who received open label atomoxetine with another drug.

Limiting the data to pediatric patients yields the following new totals for atomoxetine and placebo.

Table F4. Pediatric ADHD safety and efficacy trials: frequency of patients with adverse psychiatric events.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>1056</td>
<td>256.02</td>
<td>0</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine</td>
<td>1939</td>
<td>524.64</td>
<td>4</td>
<td>8</td>
<td>45</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine+Concerta</td>
<td>9</td>
<td>0.87</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine+Fluoxetine</td>
<td>114</td>
<td>11.92</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Fluoxetine</td>
<td>120</td>
<td>7.54</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>DB</td>
<td>Methylphenidate</td>
<td>515</td>
<td>69.21</td>
<td>0</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>Open</td>
<td>Atomoxetine</td>
<td>4669</td>
<td>4546.74</td>
<td>12</td>
<td>44</td>
<td>191</td>
</tr>
<tr>
<td>Run-in</td>
<td>Atomoxetine</td>
<td>812</td>
<td>177.80</td>
<td>2</td>
<td>3</td>
<td>47</td>
</tr>
</tbody>
</table>

Note that there were proportionally more aggression events during run-in treatment than during double blind treatment with atomoxetine. It will be seen that there is an imbalance in the numbers of patients with events in all three categories for double blind atomoxetine versus placebo, even after accounting for the approximately 2:1 ratio of patient-years of exposure. However, the imbalance for suicidal events is not as great as it was in Lilly’s previous analysis of suicidal adverse events. The present results include some additional clinical trial data that was not part of Lilly’s previous analyses. Relapse prevention trials were not included in Lilly’s analyses, and removing these two trials (HFBE and LYAF) from the pool of trials yields the following totals, which are more comparable to the previous analyses by Lilly. For simplicity, only the double blind data are shown, since the other data are not affected by removing the relapse prevention trial data.
Table F5. Pediatric ADHD safety and efficacy trials, omitting long term relapse prevention trials: frequency of patients with adverse psychiatric events.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>839</td>
<td>144.54</td>
<td>0</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine</td>
<td>1616</td>
<td>296.50</td>
<td>4</td>
<td>4</td>
<td>38</td>
</tr>
</tbody>
</table>

This subgrouping yields an incidence rate ratio for the pooled data on suicidal events of 1.9, with wide confidence limits (0.19-96, Stata 7.0). The incidence rate ratio for aggression events is 1.5 (c.i. 0.8-3.2), and due to an absence of events on placebo the ratio is undefined for psychosis/mania events, with a p-value of 0.2 for the comparison between drug and placebo.

Differences in the search strategies employed seem to account for some of the differences in the numbers of cases. In their submission dated 12-8-05, Lilly was able to reconcile the counts of cases between their own analyses of aggression and suicidal events and their response to FDA’s September 2005 request. Lilly found that certain cases from their previous analyses had not been returned in the FDA-requested search, because (1) in response to the FDA request (unlike their previous analyses) they had not searched comments fields from the case report forms, and (2) in their previous searches they had used more inclusive text strings resulting in greater sensitivity. Additionally, Lilly had potential cases adjudicated by experts prior to analyzing the data, and this was not part of the present analysis.

In addition to the pediatric ADHD trials, there was one pediatric study (LYBH) in patients with enuresis, and the data from this trial are displayed below.

Table F6. Frequency of patients with adverse events in enuresis trial LYBH

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>43</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine</td>
<td>44</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Open</td>
<td>Atomoxetine</td>
<td>64</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

The sponsor also provided the corresponding data for the adult depression trials, which is summarized below. Psychosis/mania events were more frequent among atomoxetine treated patients, while suicidal and aggressive events were less frequent, proportional to exposure time.
Table F7. Adult major depressive disorder safety and efficacy trials: frequency of patients with adverse psychiatric events.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Patient years of exposure</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>653</td>
<td>156.99</td>
<td>1</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>DB</td>
<td>Atomoxetine</td>
<td>1178</td>
<td>333.31</td>
<td>6</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Open</td>
<td>Atomoxetine</td>
<td>42</td>
<td>12.11</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

With respect to events occurring after treatment discontinuation, the sponsor provided listings of such events, but these proved difficult to analyze because the listings were not organized according to indication or category of event. The events occurring after treatment were not included in the data shown above.

G. Ritalin LA (NDA 21-284, Novartis)

Ritalin LA is an extended release formulation of methylphenidate. There were 5 controlled trials and one open label trial in the Ritalin LA development program, as summarized in Appendix table G. All trials involved only pediatric subjects.

The next table displays the summary data on the psychiatric events of interest.

Table G. Frequency of patients experiencing selected psychiatric events in Ritalin LA clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>259</td>
<td>11.31</td>
<td>0</td>
<td>1*</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Ritalin LA</td>
<td>383</td>
<td>25.66</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Open</td>
<td>Ritalin LA OL</td>
<td>125</td>
<td>25.95</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>89</td>
<td>2.82</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*One additional suicidal event occurred within 30 days of the end of treatment in a patient who had been randomized to placebo

**includes single blind Ritalin LA exposures in Protocol 07

Narratives for patients with serious adverse events and trial discontinuations for adverse events were reviewed, disclosing one event which could arguably have been included in the category of suicidal events but apparently was not: in Protocol 07, patient 503/6, an 8-year old male receiving double blind Ritalin LA, was hospitalized for suicidal ideation. The event was coded as depression and counted in the category “miscellaneous.” Although the post-treatment suicidal event involving a placebo patient was designated serious, none of the events enumerated in the table above during study treatment were considered serious.

H. Focalin (NDA 21-278) and Focalin XR (NDA 21-802) (Novartis)
Focalin and Focalin XR are drug products with dextromethylphenidate (d-MPH) as the active ingredient. The XR product is an extended release formulation. In the following data presentations the two formulations will be combined and listed as d-methylphenidate (d-mph). The trials in the sponsor’s development program for both formulations are summarized in Appendix table H. All trials involved pediatric patients except for one placebo-controlled trial in adults (E2302) which included open label follow-up treatment (designated E2302E).

The table below summarizes the numbers of events in trials with d-MPH. There were no events of interest with placebo treatment. Note that Novartis apparently included 3 events occurring after discontinuation of open-label d-MPH treatment in these counts, which was not the intention. However, because data on which category the event was classified in was not always provided in the listing of events, making it difficult to match the counts of events with particular cases in the patient listings, it was decided to leave the events in the counts displayed below rather than to try to correct the totals.

Table H1. Frequency of patients experiencing selected psychiatric events in Focalin and Focalin XR clinical safety and efficacy studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>468</td>
<td>53.24</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>d-MPH*</td>
<td>588</td>
<td>64.75</td>
<td>4</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Open</td>
<td>d-MPH*</td>
<td>740</td>
<td>362.09</td>
<td>3</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>164</td>
<td>5.89</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>dl-MPH</td>
<td>46</td>
<td>3.59</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Focalin and Focalin XR

Novartis’ analysis of these data showed that aggressive events were more frequent among males than females (data not shown).

The sponsor reported that in the clinical pharmacology studies there were no relevant psychiatric adverse events. One pediatric patient (97 M 05/2708) had a psychosis/mania event three weeks after open label treatment was discontinued (psychotic depression with homicidal ideation, requiring hospitalization). Also, there was one miscellaneous event with a serious outcome, patient 22-03 in study 97 M 04, but this patient’s event was also counted as psychosis/mania (see below).

The table below shows the data for the subgroup of trials involving only subjects of pediatric age.
### Table H2. Summary data from pediatric trials in the d-MPH development program

<table>
<thead>
<tr>
<th>Study design</th>
<th>Treatment</th>
<th>N</th>
<th>Person-yrs</th>
<th>Psychosis/mania events</th>
<th>Suicidal events</th>
<th>Aggression events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DB</td>
<td>Placebo</td>
<td>415</td>
<td>48.47</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>d-MPH*</td>
<td>420</td>
<td>49.73</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Open</td>
<td>d-MPH*</td>
<td>570</td>
<td>302.87</td>
<td>2</td>
<td>1</td>
<td>11</td>
</tr>
<tr>
<td>DB</td>
<td>Concerta</td>
<td>164</td>
<td>5.89</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DB</td>
<td>dl-MPH</td>
<td>46</td>
<td>3.59</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Focalin and Focalin XR

Review of the narratives for patients with serious adverse events and trial discontinuations disclosed two events which arguably could have been included in the category of suicidal events, but were not. Both patients were treated with open label d-MPH in study 97 M 04. Patient 22-03, a 7 year old boy, was hospitalized after placing a belt around his neck and showing aggressiveness, and hallucinating. This patient was counted in the psychosis/mania category. Patient 23-31, a 12 year old boy, was hospitalized with psychotic depression for violent behavior and suicidal and homicidal thoughts; this event was counted under psychosis/mania and aggression.

### 5. CONCLUSIONS

A. There are factors that limit the utility of these clinical trial data for determining whether any of these drugs are associated with the selected psychiatric events. Some of these limitations apply whenever clinical trial data are aggregated for analysis. For one, there is the issue of whether adverse events are ascertained with the same level of sensitivity by different investigators, and in different trials. This can present challenges when making comparisons between trials and between development programs. Secondly, there is the issue of whether cases could have been misclassified. The data presented herein were based upon each sponsor’s adverse event classifications, but the methods employed to produce these classifications varied across sponsors. Third, the statistical power of such safety analyses are always limited by the sample sizes of the trials considered.

In addition to these general limitations which apply to all such safety analyses, there are additional limitation specific to these data. First, as can be seen from the tables in the appendix, a large number of the controlled trials required subjects who were known to respond to stimulants, or who had no history of intolerance to stimulants. This tends to limit the external generalizability of safety data collected from samples of such subjects, especially when the data obtained from the subjects show relatively infrequent adverse events. Secondly, it will be seen that the duration of exposure in many of these trials was likely to have been insufficient for determination of infrequent adverse events; e.g., although over a thousand pediatric subjects received double-blind treatment in one set of clinical trials, the average duration of exposure to double-blind treatment was only 23 days. To a certain degree this can be (and was) mitigated by greater exposure time in open label trials, but open label data is of less inferential value than controlled data. The
exception to this was the development program for atomoxetine, which included over 500 person-years of double blind atomoxetine pediatric exposure.

B. Undertaking a more formal meta-analysis of the clinical trial data for these events would have presented challenges because of the sparse nature of the data; many trials had no events at all.

C. With respect to specific findings, suicidal events were more frequent with atomoxetine and modafinil treatment than with placebo. It should be noted that there were no completed suicides in ADHD trials with these drugs (one completed suicide was reported in a placebo patient in an atomoxetine trial for another indication). Aggressive events were more frequent with the methylphenidate transdermal patch, and to a lesser degree with atomoxetine, than with placebo. None of these imbalances in rates reached customary levels of statistical significance in this analysis, although Lilly’s previous analysis of suicidal events with atomoxetine did show a statistically significant association, as was summarized above. For aggression events, there was little evidence in these trials that drug treatment reduced their frequency relative to placebo; only for modafinil was the event rate numerically lower than for placebo and this was not statistically significant.

D. With respect to psychosis and mania events, although the numbers of such events with drug treatment were small, the complete absence of such events with placebo treatment was notable. For 4028 pediatric ADHD patients in these trials, there were no such events in 425 person-years of aggregated placebo treatment. Statistically, observing no events in 425 person-years yields an upper one-sided 97.5% confidence limit to the “true” event rate of 0.9 per 100 person-years. (Similarly, there were no psychosis or mania events in these trials among 578 adult ADHD patients receiving placebo for a total exposure time of 111.5 person-years in the adult age group.) Psychosis/mania events occurred during double-blind treatment with every compound except Adderall XR (although there were psychosis/mania events with open label Adderall XR treatment). Furthermore, as noted above, some subjects in Phase I studies of these drugs experienced this type of event.

E. Patients and physicians should be aware of the possibility that these events, when they arise in the course of drug treatment of ADHD, may represent adverse reactions to drugs.

F. In terms of future clinical trial designs, it should be borne in mind that short-duration trials and trials which exclude subjects who are naïve to this class of drug, while they may be efficient for determining efficacy, have limitations for defining the safety profile of the drug.

Acknowledgements
Grateful acknowledgement is made to the sponsors who provided their clinical trial data. Acknowledgement is also made to the Division of Psychiatry Products for their assistance with the data requests (Thomas Laughren, M.D., Susan Player, MS, APRN, BC, Chardae Araojo, Pharm.D., ) to Drs. Judith Racoosin and Tarek Hammad for their advice on formatting the requests, and to Dr. Kate Gelperin for her helpful comments on the analysis.
## Appendix Table A. ADHD safety and efficacy studies with Concerta included in analysis

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>C 97 025</td>
<td>1</td>
<td>6-12</td>
<td>6</td>
<td>18-54</td>
<td>68</td>
<td>MPH users</td>
<td>Included laboratory school</td>
<td>1998</td>
</tr>
<tr>
<td>C 98 003</td>
<td>1</td>
<td>6-12</td>
<td>7</td>
<td>18-54</td>
<td>62</td>
<td>MPH users</td>
<td>Included laboratory school</td>
<td>1999</td>
</tr>
<tr>
<td>C 98 005</td>
<td>14</td>
<td>6-12</td>
<td>28</td>
<td>18-54</td>
<td>104</td>
<td>MPH users or previous study subjects</td>
<td>Open label run-in phase was designated Study C 98 007</td>
<td>1998</td>
</tr>
<tr>
<td>C 98 007</td>
<td>14</td>
<td>6-12</td>
<td>21</td>
<td>18-54</td>
<td>110</td>
<td>-</td>
<td>Naïve or using drugs other than MPH</td>
<td>1998</td>
</tr>
<tr>
<td>C 98 012</td>
<td>14</td>
<td>6-13</td>
<td>&gt; 1 yr</td>
<td>18-54</td>
<td>436</td>
<td>-</td>
<td>Subjects in previous trials</td>
<td>2000</td>
</tr>
<tr>
<td>C 99 018</td>
<td>118</td>
<td>&gt; 6 incl. adults 9 mos.</td>
<td>18-54</td>
<td>1088</td>
<td>-</td>
<td>Naïve or previously drug treated</td>
<td>Long term open label</td>
<td>2001</td>
</tr>
<tr>
<td>01 146</td>
<td>15</td>
<td>13-18</td>
<td>14</td>
<td>18-72</td>
<td>87</td>
<td>ADHD</td>
<td>Randomized withdrawal design following open label run-in. Also included open label extension after DB phase</td>
<td>2002</td>
</tr>
<tr>
<td>12 101</td>
<td>323</td>
<td>6-12</td>
<td>21</td>
<td>18-72</td>
<td>~890</td>
<td>-</td>
<td>Drug naïve patients allowed</td>
<td>Randomized, open label design</td>
</tr>
<tr>
<td>C2000 045</td>
<td>11 in Europe</td>
<td>6-16</td>
<td>Up to 12 mos</td>
<td>18-54</td>
<td>105</td>
<td>-</td>
<td>MPH users</td>
<td>Long term open label</td>
</tr>
<tr>
<td>CONCAN1</td>
<td>?</td>
<td>6-12</td>
<td>8 wks</td>
<td>18-54</td>
<td>~75</td>
<td>-</td>
<td>ADHD</td>
<td>Randomized, open label</td>
</tr>
<tr>
<td>CONCAN2</td>
<td>?</td>
<td>6-13</td>
<td>6 mos.</td>
<td>18-54</td>
<td>109</td>
<td>-</td>
<td>CONCAN1 subjects</td>
<td>Open label extension</td>
</tr>
</tbody>
</table>

Abbreviations: mph methylphenidate; Xover crossover
### Appendix Table B. ADHD safety and efficacy trials with Metadate CD included in the analysis

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD 00600</td>
<td>10</td>
<td>6-12</td>
<td>7 (3-way Xover)</td>
<td>20-60</td>
<td>173</td>
<td>181</td>
<td>180 Concerta</td>
<td>Mph users</td>
</tr>
<tr>
<td>MAI 100102</td>
<td>1</td>
<td>7-12</td>
<td>7 (2 period Xover)</td>
<td>20 or 40</td>
<td>25</td>
<td>25</td>
<td>25 Mph</td>
<td>Mph users</td>
</tr>
<tr>
<td>MAI 100104</td>
<td>32</td>
<td>School age, &gt;6</td>
<td>21</td>
<td>20-60</td>
<td>158</td>
<td>163</td>
<td>-</td>
<td>Mph users</td>
</tr>
<tr>
<td>MAI 100302</td>
<td>44 (AUS, CAN, &amp; US)</td>
<td>6-12</td>
<td>21</td>
<td>20-60</td>
<td>139</td>
<td>46</td>
<td>133 Mph</td>
<td>Mph users</td>
</tr>
<tr>
<td>CD00500</td>
<td>51</td>
<td>6-17</td>
<td>-</td>
<td>20-60</td>
<td>308</td>
<td>-</td>
<td>-</td>
<td>Mph users (59% of sample) or previously untreated ADHD</td>
</tr>
<tr>
<td>MAI 100103</td>
<td>1</td>
<td>6-11</td>
<td>49</td>
<td>10-30</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>Previously untreated ADHD</td>
</tr>
</tbody>
</table>

Abbreviations: mph methylphenidate; Xover crossover
### Appendix Table C. ADHD safety and efficacy trials with methylphenidate transdermal system (MTS) included in the analysis

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>N17-002</td>
<td>1</td>
<td>6-9</td>
<td>7 (3-way Xover)</td>
<td>10 cm²</td>
<td>10</td>
<td>10 Mph</td>
<td>ADHD</td>
<td>Laboratory classroom</td>
</tr>
<tr>
<td>N17-003</td>
<td>1</td>
<td>6-10</td>
<td>2 Xover</td>
<td>2.5-20 cm²</td>
<td>13</td>
<td>13 -</td>
<td>ADHD</td>
<td>Laboratory classroom</td>
</tr>
<tr>
<td>N17-009</td>
<td>3</td>
<td>6-12</td>
<td>1</td>
<td>6.25-25 cm²</td>
<td>36</td>
<td>36 -</td>
<td>ADHD</td>
<td>Summer camp</td>
</tr>
<tr>
<td>N17-015</td>
<td>1</td>
<td>6-12</td>
<td>1 (multiple Xover)</td>
<td>6.25-25 cm²</td>
<td>27</td>
<td>27 -</td>
<td>ADHD</td>
<td>Summer camp</td>
</tr>
<tr>
<td>SPD485201</td>
<td>6</td>
<td>6-12</td>
<td>35d Open label, then 7d 2-way Xover</td>
<td>12.5-37.5 cm²</td>
<td>80</td>
<td>79 -</td>
<td>ADHD and no comorbid disorders except ODD</td>
<td>Laboratory classroom</td>
</tr>
<tr>
<td>N17-010</td>
<td>20</td>
<td>6-12</td>
<td>21</td>
<td>6.25-25 cm²</td>
<td>101</td>
<td>109 -</td>
<td>ADHD</td>
<td>2001</td>
</tr>
<tr>
<td>N17-018</td>
<td>21</td>
<td>6-12</td>
<td>28</td>
<td>6.25-50 cm²</td>
<td>106</td>
<td>105 -</td>
<td>ADHD with or without current drug treatment</td>
<td>2002</td>
</tr>
<tr>
<td>SPD485302</td>
<td>38</td>
<td>6-12</td>
<td>49</td>
<td>12.5-37.5 cm²</td>
<td>98</td>
<td>85 91 Concerta</td>
<td>Stimulant nonresponders excluded</td>
<td>2005</td>
</tr>
<tr>
<td>N17-011</td>
<td>Multi</td>
<td>6-12</td>
<td>90</td>
<td>6.25-25 cm²</td>
<td>118</td>
<td>- -</td>
<td>ADHD</td>
<td>Open label only</td>
</tr>
<tr>
<td>N17-013</td>
<td>Multi</td>
<td>6-12</td>
<td>Until NDA approved</td>
<td>6.25-37.5 cm²</td>
<td>20</td>
<td>ongoi -</td>
<td>Responders to mph patch in previous protocols</td>
<td>Continued open label treatment for patients who had positive response</td>
</tr>
</tbody>
</table>
### Appendix Table D. ADHD safety and efficacy studies with modafinil included in the analysis

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>205</td>
<td>6 (phase A) 7 (phase B)</td>
<td>Adults 18-57</td>
<td>6 wks</td>
<td>100, 200, 400 (fixed)</td>
<td>109 (74 phase A, 35 phase B)</td>
<td>ADHD without psychiatric comorbidity</td>
<td>Included 8 week open label extension</td>
<td>2001</td>
</tr>
<tr>
<td>207</td>
<td>3</td>
<td>6-13</td>
<td>1 wk 4 way Xover</td>
<td>0, 100, 200, 300/400</td>
<td>46</td>
<td>ADHD</td>
<td>Included 8 wk open label extension</td>
<td>2000</td>
</tr>
<tr>
<td>213</td>
<td>28</td>
<td>6-13</td>
<td>4 wks</td>
<td>300 or 400</td>
<td>197</td>
<td>ADHD, either stimulant-naive or -tolerant</td>
<td>Included 8 wk open label extension</td>
<td>2002</td>
</tr>
<tr>
<td>309</td>
<td>18</td>
<td>6-17</td>
<td>9 wk</td>
<td>170-425</td>
<td>131</td>
<td>ADHD without psychiatric comorbidity</td>
<td>Parallel group, 2:1 randomization</td>
<td>2004</td>
</tr>
<tr>
<td>310</td>
<td>17</td>
<td>6-17</td>
<td>9 wk</td>
<td>340 or 425 according to wt</td>
<td>125</td>
<td>ADHD without psychiatric comorbidity</td>
<td>At week 7 modafinil patients were randomized to either modafinil or pbo for final 2 wks</td>
<td>2004</td>
</tr>
<tr>
<td>311</td>
<td>24</td>
<td>6-17</td>
<td>9 wk</td>
<td>170-425</td>
<td>164</td>
<td>ADHD without psychiatric comorbidity</td>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>113</td>
<td>1</td>
<td>6-13</td>
<td>2 wks + 2 single doses</td>
<td>340,425</td>
<td>24</td>
<td>ADHD not responding well to medication</td>
<td>Bioavailability assessment was main objective</td>
<td>2003</td>
</tr>
<tr>
<td>206</td>
<td>3</td>
<td>6-12</td>
<td>4 wks</td>
<td>100-400</td>
<td>20</td>
<td>ADHD without</td>
<td>Included optional 8 wk</td>
<td>2000</td>
</tr>
</tbody>
</table>

Abbreviations: mph methylphenidate; Xover crossover
<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Drug</th>
<th>Pbo.</th>
<th>Active control</th>
<th>Population Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>201</td>
<td>4</td>
<td>6-12</td>
<td>1 wk X over (5 way)</td>
<td>Adderall 10, Adderall XR 10, 20, 30</td>
<td>50</td>
<td>49</td>
<td>-</td>
<td>-</td>
<td>Current users of Adderall or MPH</td>
<td>Laboratory school setting</td>
</tr>
<tr>
<td>301</td>
<td>47</td>
<td>6-12</td>
<td>3 wks</td>
<td>10, 20, 30 (fixed)</td>
<td>10 mg 129; 20 mg 121; 30 mg 124</td>
<td>210</td>
<td>-</td>
<td>-</td>
<td>ADHD, known to be tolerant of stimulants</td>
<td>2000</td>
</tr>
<tr>
<td>302</td>
<td>49</td>
<td>6-12</td>
<td>24 mos.</td>
<td>10-30</td>
<td>568</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Participants in previous trials</td>
<td>Open label, long term safety</td>
</tr>
<tr>
<td>303</td>
<td>18</td>
<td>≥18</td>
<td>4 wks</td>
<td>20, 40, 60 (fixed)</td>
<td>191</td>
<td>64</td>
<td>-</td>
<td>-</td>
<td>Adults with ADHD and no history of intolerance to stimulants</td>
<td>2002</td>
</tr>
<tr>
<td>304</td>
<td>18</td>
<td>≥18</td>
<td>24 mos.</td>
<td>20, 40, or 60</td>
<td>223</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Adults who participated in study 303</td>
<td>Open label, long term safety</td>
</tr>
<tr>
<td>305</td>
<td>365</td>
<td>6-12</td>
<td>15 wks</td>
<td>10-40</td>
<td>2968</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Responders to prior stimulant treatment</td>
<td>Open label safety and efficacy</td>
</tr>
<tr>
<td>311</td>
<td>27</td>
<td>6-17</td>
<td>4 wks</td>
<td>10, 20, 30, 40 fixed dose</td>
<td>237</td>
<td>60</td>
<td>-</td>
<td>-</td>
<td>Oppositional defiant disorder (not ADHD)</td>
<td>2003</td>
</tr>
<tr>
<td>312</td>
<td>81 (U.S., Canada)</td>
<td>≥18</td>
<td>40 wks</td>
<td>10-60</td>
<td>725</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Previously treated or naive</td>
<td>2005</td>
</tr>
<tr>
<td>314a</td>
<td>50</td>
<td>13-17</td>
<td>4 wks</td>
<td>10, 20, 30, 40 (fixed)</td>
<td>258</td>
<td>69</td>
<td>-</td>
<td>-</td>
<td>ADHD, no special requirements</td>
<td>2003</td>
</tr>
<tr>
<td>314b</td>
<td>32</td>
<td>13-17</td>
<td>6 mos.</td>
<td>10-60</td>
<td>138</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Subjects in study 314a</td>
<td>Long term extension of 314a</td>
</tr>
<tr>
<td>Protocol</td>
<td>No. of sites</td>
<td>Age range (yrs)</td>
<td>Duration (wks)</td>
<td>Dose (mg/day)</td>
<td>N</td>
<td>Drug</td>
<td>Placebo</td>
<td>Active control</td>
<td>Population</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>----------------</td>
<td>----------------</td>
<td>---------------</td>
<td>---</td>
<td>------</td>
<td>---------</td>
<td>----------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>HFBD</td>
<td>9</td>
<td>7-12</td>
<td>9</td>
<td>2 mg/kg/d</td>
<td>65</td>
<td>62</td>
<td>20 Mph</td>
<td>ADHD, with or without prior stimulant tx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFBK</td>
<td>10</td>
<td>7-12</td>
<td>9</td>
<td>2 mg/kg/d</td>
<td>64</td>
<td>62</td>
<td>18 Mph</td>
<td>ADHD, with or without prior stimulant tx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYAA</td>
<td>17</td>
<td>≥18</td>
<td>10</td>
<td>60,90,120</td>
<td>141</td>
<td>139</td>
<td>-</td>
<td>Adult ADHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYAC</td>
<td>13</td>
<td>8-17</td>
<td>8</td>
<td>1.2 or 1.8 mg/kg/d</td>
<td>213</td>
<td>84</td>
<td>-</td>
<td>ADHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYAO</td>
<td>14</td>
<td>≥18</td>
<td>10</td>
<td>60,90,120</td>
<td>129</td>
<td>127</td>
<td>-</td>
<td>Adult ADHD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYAS</td>
<td>15</td>
<td>7-17.5</td>
<td>18</td>
<td>0.5,1,1.5 mg/kg/d</td>
<td>76</td>
<td>72</td>
<td>-</td>
<td>ADHD plus tic disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LYAT</td>
<td>9</td>
<td>6-16</td>
<td>6</td>
<td>0.75-1.5 mg/kg/d</td>
<td>85</td>
<td>86</td>
<td>-</td>
<td>ADHD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*data not provided

Appendix Table F. ADHD safety and efficacy studies with atomoxetine included in the analysis
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Age Range</th>
<th>Duration</th>
<th>Dose</th>
<th>Outcome</th>
<th>Design Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYAW</td>
<td>11</td>
<td>8-12</td>
<td>7</td>
<td>0.8-1.8 mg/kg/d</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYAX</td>
<td>16</td>
<td>12-17</td>
<td>9</td>
<td>0.8-1.8 mg/kg/d</td>
<td>ADHD plus major depression</td>
</tr>
<tr>
<td>LYBG</td>
<td>12</td>
<td>6-12</td>
<td>8</td>
<td>0.8-1.8 mg/kg/d</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYBI</td>
<td>21</td>
<td>6-16</td>
<td>6</td>
<td>0.8-1.8 mg/kg/d</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYBP</td>
<td>14</td>
<td>8-17</td>
<td>12</td>
<td>0.8-1.8 mg/kg/d</td>
<td>ADHD plus anxiety disorder</td>
</tr>
<tr>
<td>LYCC</td>
<td>14</td>
<td>6-12</td>
<td>6</td>
<td>0.8-1.4 mg/kg/d</td>
<td>ADHD per DSM-IV-TR</td>
</tr>
<tr>
<td>HFBC</td>
<td>1</td>
<td>7-13</td>
<td>100 dys</td>
<td>10-90</td>
<td>ADHD</td>
</tr>
<tr>
<td>HFBF</td>
<td>23</td>
<td>7-16</td>
<td>48 wks</td>
<td>5-90</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYAB</td>
<td>53</td>
<td>6-18</td>
<td>2 yrs</td>
<td>≤1.8 mg/kg/d</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYAF</td>
<td>33 International</td>
<td>6-15</td>
<td>78 wks</td>
<td>≤1.8 mg/kg/d</td>
<td>ADHD</td>
</tr>
<tr>
<td>LYAI</td>
<td>31</td>
<td>6-17</td>
<td>-</td>
<td>-</td>
<td>Subjects in previous atomoxetine trials</td>
</tr>
<tr>
<td>LYAQ</td>
<td>21</td>
<td>6-17</td>
<td>6 wks</td>
<td>≤1.8 mg/kg/d</td>
<td>ADHD plus anxiety or depressive disorder</td>
</tr>
<tr>
<td>LYAR</td>
<td>30</td>
<td>≥18</td>
<td>Open ended</td>
<td>Up to 120</td>
<td>Adult ADHD</td>
</tr>
<tr>
<td>LYAU</td>
<td>1</td>
<td>6-13</td>
<td>6 wks, 2 way Xover</td>
<td>0.5 – 1.8 mg/kg/d</td>
<td>ADHD, right handed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td></td>
</tr>
<tr>
<td>ongoing</td>
<td></td>
</tr>
<tr>
<td>ongoing</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td></td>
</tr>
<tr>
<td>ongoing</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td></td>
</tr>
<tr>
<td>Protocol</td>
<td>No. of sites</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>LYAV</td>
<td>2</td>
</tr>
<tr>
<td>LYBB</td>
<td>40</td>
</tr>
<tr>
<td>LYBD</td>
<td>19 (Japan)</td>
</tr>
<tr>
<td>LYBM</td>
<td>14</td>
</tr>
<tr>
<td>LYBR</td>
<td>13</td>
</tr>
<tr>
<td>LYBU</td>
<td>5</td>
</tr>
<tr>
<td>LYBV</td>
<td>23</td>
</tr>
<tr>
<td>LYCI</td>
<td>6</td>
</tr>
</tbody>
</table>

Appendix Table G. ADHD safety and efficacy trials with Ritalin LA included in the analysis
US02  12-17 **  **  99 102 - ** All females **
US05  6-12 Single dose, 4-way Xover 20 36 36 36 Concerta Mph users Laboratory classroom 2002
US07  6-12 Single dose, 5-way Xover 20 and 40 53 53 53 Concerta (two doses) Mph users Laboratory classroom 2003
07 E1 ** <17 ** ** 125 - - ** Open label **

*There were no events in Protocol 02. Data were not available by specific treatment, and so were not included in the pooled analysis.
**information not available

Appendix Tables H. ADHD safety and efficacy trials with d-methylphenidate included in the analysis

Focalin XR

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2301</td>
<td>12</td>
<td>6-17</td>
<td>49</td>
<td>5-30</td>
<td>53 47 -</td>
<td>Mph users or naïve</td>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>2302</td>
<td>18</td>
<td>18-60</td>
<td>35</td>
<td>20,30,40</td>
<td>165 53 -</td>
<td>Adults with ADHD</td>
<td></td>
<td>2003</td>
</tr>
<tr>
<td>US08</td>
<td>3</td>
<td>6-12</td>
<td>6 (2-way Xover)</td>
<td>20</td>
<td>54 54 -</td>
<td>Mph users Laboratory classroom setting</td>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>2302E1</td>
<td>18</td>
<td>18-60</td>
<td>6 mos.</td>
<td>10-40</td>
<td>170 - -</td>
<td>Adults with ADHD Open label follow-up to study 2302</td>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>US09</td>
<td>4</td>
<td>6-12</td>
<td>7 (2 way Xover)</td>
<td>20</td>
<td>68 68 -</td>
<td>Stable users of Mph Laboratory classroom setting</td>
<td></td>
<td>2004</td>
</tr>
<tr>
<td>US12</td>
<td>*</td>
<td>6-12</td>
<td>*</td>
<td>20,30</td>
<td>84 83 83 Concerta *</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>US13</td>
<td>*</td>
<td>6-12</td>
<td>*</td>
<td>20,30</td>
<td>82 81 81 Concerta *</td>
<td></td>
<td>5-way Xover *</td>
<td></td>
</tr>
</tbody>
</table>

*information not available
<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of sites</th>
<th>Age range (yrs)</th>
<th>Duration (dys)</th>
<th>Dose (mg/day)</th>
<th>N</th>
<th>Population</th>
<th>Comments</th>
<th>Study completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>97-M-02</td>
<td>12</td>
<td>6-17</td>
<td>28</td>
<td>5-20 mph; 10-40 mph</td>
<td>44</td>
<td>42</td>
<td>46 (mph)</td>
<td>ADHD</td>
</tr>
<tr>
<td>97-M-03</td>
<td>7</td>
<td>6-17</td>
<td>42 wk open label</td>
<td>5-20</td>
<td>35</td>
<td>40</td>
<td>-</td>
<td>ADHD</td>
</tr>
<tr>
<td>97-M-04</td>
<td>8</td>
<td>6-17</td>
<td>1 yr</td>
<td>5-20</td>
<td>187</td>
<td>-</td>
<td>-</td>
<td>ADHD</td>
</tr>
<tr>
<td>97-M-05</td>
<td>27 (U.S. and Canada)</td>
<td>6 mo</td>
<td>5-20</td>
<td>361</td>
<td>-</td>
<td>-</td>
<td>ADHD</td>
<td>Long term open label</td>
</tr>
<tr>
<td>00-M-06</td>
<td>2</td>
<td>6-18</td>
<td>8 wk</td>
<td>2.5-30</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>ADHD</td>
</tr>
<tr>
<td>00-M-07</td>
<td>?</td>
<td>Adult 12 wk</td>
<td>5-50</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>Adults with ADHD</td>
<td>Open label pilot, data not provided</td>
</tr>
</tbody>
</table>